

PRE-I-SPY TRIAL - PRE-Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis: A Phase I/Ib platform trial

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy
volunteers

Inclusion Criteria:

1. have HER2+ breast cancer 2. cancer has spread to other organs or returned within 6 months after first treatment

Exclusion Criteria:

1. active heart or liver disease 2. cancer has spread to the brain and is causing current symptoms

Conditions & Interventions

Conditions:

Cancer, Women's Health

Keywords:

Clinics and Surgery Center (CSC), Breast Cancer, Breast Cancer, HER2+ breast cancer, ISPY

More Information

Description: This study is intended to find the safest dose of a new combination of drugs (ALX148 and T-DXd) and to start to determine how effective it is at treating advanced or metastatic breast cancer. This study is an addition to the ongoing ISPY study program.

Study Contact: David Potter - dapotter@umn.edu

Principal Investigator: David Potter

IRB

Number: SITE00001846

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.